Clincosm LogoSign in Get a demo

CC2017: Antagonist Activation Measurement at the Ankle Using High-density and Bipolar Surface EMG in Chronic Hemiparesis

Sponsor
Henri Mondor University Hospital (Other)
Overall Status
Completed
CT.gov ID
NCT06099132
Collaborator
(none)
12
Enrollment
12
Actual Duration (Months)

Study Details

Study Description

Brief Summary

In chronic hemiparesis, abnormal antagonist muscle activation in the paretic lower limb contributes to impair ambulation capacities. A biased estimate of antagonist muscle activation when using surface bipolar EMG compared with high-density (HD) EMG has been previously reported in healthy subjects. The present study compares muscles cocontraction at the paretic ankle estimated with a pair of and multi-channel surface EMG.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Electromyographic measurements

Detailed Description

In chronic hemiparesis, gait velocity deficit is associated with a disturbed voluntary movement caused especially by inappropriate antagonist muscle activation. The present study investigates muscles cocontraction at the paretic ankle estimated with a pair of and multi-channel surface EMG (HD-EMG) in patients after stroke. HD-EMGs were collected from gastrocnemius medialis (GM), tibialis anterior (TA) and soleus (SO) during isometric contractions. From these EMGs the study asked whether bipolar and HD-EMGs provided comparable estimates of antagonist activation. Two active contraction levels (submaximal vs. maximal) and knee positions (flexed vs. extended) were assessed for each muscle. Notwithstanding the evidence of localized antagonist activation in the GM muscle of healthy subjects, hypothesizing equally localized antagonist activation in the paretic limb may not follow from the current literature. In virtue of evidence supporting the enlargement of motor unit territories in paretic and hyperactive muscles, it may be that stroke survivors have lost their ability to regionally and appropriately activate their muscle. In this case, bipolar and HD-EMG would be expected to provide comparable antagonist activation coefficients.

Study Design

Study Type:
Observational
Actual Enrollment :
12 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Antagonist Activation Measurement at the Ankle Using High-density and Bipolar Surface EMG in Chronic Hemiparesis
Actual Study Start Date :
Jan 1, 2017
Actual Primary Completion Date :
Dec 31, 2017
Actual Study Completion Date :
Dec 31, 2017

Outcome Measures

Primary Outcome Measures

  1. Coefficient of ANtagonist activation [5 seconds]

    The Coefficient of ANtagonist activation of 3 muscles was calculated by the ratio between the root mean square amplitude during antagonist effort and maximal agonist effort for the same muscle.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:

  • hemiparesis due to a non-evolutive central nervous system lesion

  • time since lesion ≥ 6 months

  • ability to walk 10 meters barefoot without any assistance

  • cognitive abilities to understand the verbal instructions for the test according to the investigator's judgment

  • absence of botulinum toxin injections within the last 3 months prior to enrolment

Exclusion Criteria:
  • botulinum toxin injections within the last 3 months prior to enrolment

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Henri Mondor University Hospital

Investigators

  • Study Director: Emilie Hutin, Hôpitaux Universitaires Henri Mondor

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Emilie Hutin, Director, Henri Mondor University Hospital
ClinicalTrials.gov Identifier:
NCT06099132
Other Study ID Numbers:
  • CC2017
First Posted:
Oct 25, 2023
Last Update Posted:
Oct 25, 2023
Last Verified:
Oct 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:
Muscle Spasticity
Paresis
Muscle Hypertonia

Study Results

No Results Posted as of Oct 25, 2023